Compare JOE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | CRNX |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 2002 | 2018 |
| Metric | JOE | CRNX |
|---|---|---|
| Price | $67.45 | $83.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $76.75 |
| AVG Volume (30 Days) | 206.1K | ★ 3.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 56.69 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $513,246,000.00 | $1,039,000.00 |
| Revenue This Year | N/A | $720.10 |
| Revenue Next Year | N/A | $184.67 |
| P/E Ratio | $70.93 | ★ N/A |
| Revenue Growth | ★ 27.44 | N/A |
| 52 Week Low | $46.37 | $26.50 |
| 52 Week High | $73.54 | $84.09 |
| Indicator | JOE | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 71.26 | 89.87 |
| Support Level | $66.12 | $43.40 |
| Resistance Level | $72.64 | $84.00 |
| Average True Range (ATR) | 1.93 | 0.21 |
| MACD | 0.67 | -1.71 |
| Stochastic Oscillator | 99.74 | 73.17 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.